Rhodes Pharmaceuticals
Last updated Jun 25, 2026
Evidence Sources
3
Competitive Findings
0
Portfolio Developments
0
Regulatory Precedents
8
Clinical Programs
0
Confidence Coverage
65%
Audit
- Competitor findings: 0
- Portfolio developments: 0
- Self-competition findings removed: 0
- Unknown ownership findings removed: 0
Executive Summary
Material intelligence activity detected across:
- Pain Management
- Opioid
Highest priority development: FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)
Regulatory precedent
Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as Rhodes Pharmaceuticals; the same agency is already in play for this signal, so precedent weight is higher.
Competitive pressure: Low
Portfolio impact: Moderate
Evidence coverage: 65%
Active Signals
2
Investigate Priority
0
Opportunity Score
34
Buyer Quality
6 · Emerging
Recent Signals
Latest intelligence events linked to this organization.
- MonitorJun 25, 2026Score 17FDA Approves Oxycodone Hydrochloride Supplement by Rhodes Pharmaceuticals
Pain Management · Opioid
- MonitorJun 24, 2026Score 17FDA Accepts Supplemental NDA for Dilaudid by Rhodes Pharmaceuticals
Pain Management · Opioid
Related Assets
Portfolio asset pages with evidence-based assessments.
No linked asset pages are available yet.
Portfolio Development
Owned-asset pipeline events — Phase III readouts, approvals, label expansions, and deals. Not classified as competitive threats.
No portfolio development items are linked to this company yet.
Competitive Intelligence Findings
Competitiva findings with evidence, reasoning, and confidence calibration.
No Competitiva findings are linked to this company yet.
Regulatory Developments
Regunera precedents with source attribution and confidence disclosure.
- FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera - FDA AP — OXYCODONE HYDROCHLORIDE (SUPPL)Moderate Confidence · 66%
Regulatory precedent may inform portfolio positioning
Sources (3)FDAFDARegunera
Clinical Developments
Pipeline activity with auditable evidence and uncertainty disclosure.
No clinical developments are linked yet.
Investigate-Priority Items
Signals flagged for investigation or escalation — highest urgency for portfolio review.
No investigate-priority signals are active for this company.
Humanexa Agent Questions
Suggested prompts to explore this organization's intelligence profile. Open a linked signal to ask the agent.
- What are the most material competitive threats to Rhodes Pharmaceuticals right now?
- Which regulatory precedents should Rhodes Pharmaceuticals monitor in Pain Management and Opioid?
- Which pipeline programs should Rhodes Pharmaceuticals prioritize for competitive review?
- What signals require immediate investigation for Rhodes Pharmaceuticals?
- Summarize the strategic implications of recent developments for Rhodes Pharmaceuticals.
- Where is the greatest uncertainty in Rhodes Pharmaceuticals's competitive positioning?